Clinical Trial Detail

NCT ID NCT02613598
Title Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors University of Michigan Cancer Center

non-Hodgkin lymphoma

Hodgkin's lymphoma


Bortezomib + Ruxolitinib

Age Groups: adult

No variant requirements are available.